Yahoo Poland Wyszukiwanie w Internecie

Search results

1. www.nature.com › articles › s41401/022/00900-yAll about NASH: disease biology, targets, and opportunities on...

   www.nature.com › articles › s41401/022/00900-y

   4 kwi 2022 · What are the biological basis and valid drug targets of NASH? What are the key regulatory issues? How to overcome the obstacles ahead on the road to the first NASH drug?

   • Editorials

     Browse the archive of articles on Acta Pharmacologica Sinica

   • Sign up for Alerts

     Chętnie wyświetlilibyśmy opis, ale witryna, którą oglądasz,...

   • RSS Feed

     APS (Acta Pharmacologica Sinica) publishes high quality...

   • Subscribe

     Description. APS (Acta Pharmacologica Sinica) publishes high...

   • Current Issue

     Cover Credit: Lonicerin (LCR), a bioactive compound found in...

2. www.nature.com › articles › s41598/021/84577-zThe incidence trends of liver cirrhosis caused by nonalcoholic...

   www.nature.com › articles › s41598/021/84577-z

   4 mar 2021 · Globally, the incidence of liver cirrhosis caused by NASH increased from 178,430 cases in 1990 to 367,780 cases in 2017, an increase of approximately 105.56%.

3. www.expresspharma.in › madrigals-efforts-for-resmetirom-will-set-tone-for-futureMadrigal’s efforts for resmetirom will set tone for future...

   www.expresspharma.in › madrigals-efforts-for-resmetirom-will-set-tone-for-future

   • Zapisane w pamięci cache

   7 gru 2023 · Following the FDA’s acceptance of Madrigal Pharmaceuticals’ new drug application (NDA) and priority review for its THR-β agonist (resmetirom) in non-alcoholic steatohepatitis (NASH) in September 2023, the company has taken steps to fortify its leadership and financial position to gear up for the imminent launch of resmetirom.

4. www.gastroenterologyandhepatology.net › archives › july-2023Update on Clinical Trials for Nonalcoholic Steatohepatitis

   www.gastroenterologyandhepatology.net › archives › july-2023

   • Zapisane w pamięci cache

   Although multiple potential targets for drug development exist, there have been no approved therapies for NAFLD/NASH. Lipotoxicity, owing to increased delivery of fatty acids to the liver, and hepatic de novo lipogenesis are key drivers of disease pathogenesis.

5. sonyhall.com › events › our-houseOur House - Sony Hall

   sonyhall.com › events › our-house

   • Zapisane w pamięci cache

   6 dni temu · Prepare for an unparalleled musical experience as “Our House: The Music of CSNY” assembles to perform the Crosby, Stills, Nash & Young repertoire with an extraordinary ensemble of Family & Friends.

6. variety.com › 2024 › musicStephen Stills on Crosby, Stills, Nash & Young's 'Fillmore ... -...

   variety.com › 2024 › music

   • Zapisane w pamięci cache

   31 paź 2024 · Stephen Stills talks about discovering tapes of one of CSNY's first shows, his renewed relationship with Neil Young, and the memory of David Crosby.

7. www.targetrwe.com › research › newsTARGET-NASH Observational Study Reaches 5,000 Enrolled Patients

   www.targetrwe.com › research › news

   • Zapisane w pamięci cache

   14 kwi 2020 · TARGET-NASH is now the largest active observational and longitudinal NASH-specific study in the world. “TARGET-NASH has reached 5,000 enrolled patients in only its fourth year of data collection,” said TARGET PharmaSolutions CEO, Neal Bibeau.